Thank you very much for submitting your research manuscript for consideration to The EMBO Journal editorial office.
I have received a full set of comments (enclosed below) on your paper that outlines possible contributions of Egr-1 signaling to insulin sensitivity. As you will see, the referees appreciate this interesting and clinically relevant proposal. However, they also raise important points that would need to be experimentally addressed before we would be able to reach a final decision on suitability of your study for publication here.
Specifically, experiments demonstrating the proportion of adipocytes in injected epididymal fat pads that express the virus, and whether viral expression indeed originates from adipocytes or rather nonadipocytic cell types, such as macrophages. Further, more detailed in vivo studies on the metabolic phenotypes and in general better data quantification would be essential to corroborate the proposed Egr-1's function. As definitive molecular insight is a critical measure for consideration at The EMBO Journal, I urge you to take these remarks serious and invest the necessary time and experimental efforts to convince our referees from the significance of your findings. This should also avoid later disappointments. I like to add that we are able to grant additional time beyond our usual three-month deadline to facilitate requested experimentation upon authors request.
Finally, I do have to remind you that it is EMBO_J policy to allow a single round of major revisions and that the final decision on acceptance or rejection entirely depends on the content and strength of the final version of your manuscript. In case of further questions please do not hesitate to contact me, preferably via E-mail.
Looking forward to assess your revised manuscript.
Yours sincerely, Editor
The EMBO Journal REFEREE REPORTS:
Referee #1:
The manuscript by Yu et al elucidated the role of EGR1 in regulating insulin sensitivity through modulating PI3K/AKT and MAPK signaling pathways. The authors showed that EGR1 expression was elevated in diabetic rodents and patients. Overexpession of EGR1 or inhibiting EGR1 in adipocytes or adipose tissue in mice led to insulin resistance or enhanced insulin sensitivity, respectively. The findings are interesting and reveal a new role for EGR1 in regulating insulin sensitivity in adipose. The manuscript was well written. The experiments were carried out carefully and the data quality is adequate. Additional questions and comments for the authors are listed below.
1. The authors showed that EGR1 expression was elevated in adipose tissue from diabetic patients and db/db mice compared with their controls. It is important to find out whether EGR1 expression was elevated in insulin resistant, a prediabetic state, or only in diabetic state. This is can be done by using ob or diet-induced obese C57bl6 mice. 2. The information on patients' BMI has to be included in the supplemental Table 1 . In addition, information on which adipose depot where biopsies were taken from patients needs to be include. It has been shown that the gene expression in each fat depot and their contribution to insulin resistant is quite different.
3. In fig3, 4 and 5 where the authors either overexpressed EGR1, dnEGR1 or siEGR1 in adipocytes, were these human adipocytes or 3T3-L1 adipocytes? It needs to be clarified in the text or fig legends. Does overexpression of EGR1 or blocking EGR1 activity with dnEGR1 or siEGR1 affect the differentiation of adipocytes? It it does, it will complicated the interpretation of the data since dedifferentiation of adipocytes will affect insulin sensitivity and glucose uptake. The authors should measure the expression of GLUT4, PPARg, C/EBPa and adipsin which are markers of adipocyte differentiation in these in vitro experiments.
Referee #2:
In this paper, the authors explore the concept that the hyperinsulinemia of chronic insulin resistant states can cause insulin resistance by signaling through Map kinase and JNK1 pathways leading to Egr-1 expression. This concept of mixed insulin resistance has received a great deal of attention over many years, and, in these studies, the authors add to the information base on this subject. They implicate insulin mediated Egr-1 expression as a culprit which can eventually cause insulin resistance. However, there are a number of questions that should be resolved in these experiments.
1.
In all studies on this subject, there is the usual chicken and egg issue. If the hyperinsulinemia is necessary to cause insulin resistance in the author's model, then what causes the hyperinsulinemia in the first place? Usually, one thinks of insulin resistance as the cause of the hyperinsulinemia, not the other way around. Therefore, are the authors really proposing that there is some other cause of insulin resistance and that the resulting hyperinsulinemia then makes it worse through the Egr-1 mechanism?
2.
In Figure 1 the loading levels are clearly unequal between normal and diabetics in Figure  1A . This clearly skews the results, and the data need to be accurately quantitated as a ratio of Egr1 or GGPPS to actin. The relationship between Figure 1 and Supplemental Figure 1 is not clear. Is the Supplemental figure the scanned results of the blots shown in Figure 1 ? How many replicates were performed in Figure 1A , C, E, and G, and please be explicit as to the quantitation of these Western blots by scanning and statistics.
3.
Supplemental Fig. 2 . It appears that there are small differences in body weight in the db/db mouse and over 7 days this could be significant. There also appears to be changes in food intake in the wild types with adenovirus injection. Could these changes affect the in vivo metabolic data?
4.
Adenoviral injection directly into tissues has been tried many times, and the key question is not whether or not the viral encoded genes are expressed in the injected tissue, but what percentage of the cells in the tissue express the gene. In other words, is Egr-1 expressed in 10% of the cells or 90% of the total adipocytes in the depot? Also, since the injections were into adipose tissue of obese mice, how much of the Egr-1 is being expressed in non-adipocyte cell types in the adipose tissue, such as immune cells?
5.
Given the known effects of Egr-1, by what mechanism do the authors think IRS1 phosphorylation increases in Figure 2 , and how are the effects transmitted to the liver? 6.
In the signaling studies, the authors are hypothesizing that Egr-1 "tilts the balance" of PI3 kinase/Akt signaling. However, while Akt is measured, no measures of PI3 kinase are included. It is mandatory that direct measures of PI3 kinase activity be provided throughout these experiments.
7.
In Figure 4 , they provide nice evidence for the effect of Egr-1 mediated through PTEN and GGPPS. These studies again call for direct measurements of PI3 kinase. Given the targets of PTEN and GGPPS, how do the authors interpret the increased p-IRS-I data in Figure 2? 8.
In Figures 5A&B, they conduct long term experiments with insulin treatment. However, it has been well described that chronic hyperinsulinemia in vitro leads to dramatic down regulation of the insulin receptor and this would be through a mechanism that has nothing to do with the Egr-1 story. In what way can they show that the effects they observed are due to the Egr-1 mechanism and not do to the well known insulin receptor down regulation? Furthermore, chronic hyperinsulinemia has been shown to increase IRS1 serine phosphorylation, which decreases downstream IRS1 signaling. Therefore, there are plenty of mechanisms already published, independent of Egr-1 which explains all of these results. In fact, wouldn't the dnEgr1 experiment indicate that the effects of insulin on receptor down regulation and IRS1 serine phosphorylation are blocked. This would be contrary to the authors' hypothesis, but measurements of insulin receptor surface content and IRS1 serine phosphorylation must be provided.
9.
It is hard to see that the small differences in glucose levels in Figure 5E are meaningful. Given the large changes in 5D, it is hard to reconcile the small changes in 5E.
10.
As a general comment, the measures of insulin sensitivity and glucose homeostasis are a bit superficial. This study would be greatly strengthened by more measurements of insulin secretion, circulating insulin levels, as well as glucose clamp studies in the various mouse models.
11
. Figure 5A is interesting, but these are cytokines not adipokines and the authors do not know the cellular origin of the cytokines. This begs the question as to what is the effect on circulating concentrations of adiponectin and leptin. This should be provided.
12. In Figure 6D , the authors conclude that Egr-1 overexpression in fat blocked insulin induced Akt phosphorylation in the liver of BKs WT mice. However, there are two individual mice presented and pAkt looks very similar to GFP treatment in the first individual.
13.
The co-culture experiments in Figure 6F don't make much sense. They are showing that the co-culture changes insulin stimulated glucose uptake in hepatocytes. However, insulin has no effect to stimulate glucose uptake in hepatocytes, unlike its well known effects in adipocytes and muscle cells. Therefore, how can they have insulin stimulated glucose uptake effects on this process with the various co-culture conditions measured, since it is not a part of insulin action in liver.
14.
In general, the manipulations of PTEN and GGPPS are interesting, but throughout the paper the authors tend to conflate these two discrete effects, since they are both end points of Egr-1s transcriptional effects. For example, the GGPPS adipocyte knockout mouse would be an interesting story all by itself, and the data presented in this manuscript on this interesting mouse model are very preliminary and superficial.
15.
Egr-1 has been reported to have potent effects on adipocytes biology, independent of insulin signaling. In the discussion, the authors mention unpublished data on adipocyte size, etc. This should be presented in the manuscript, since changes in adipocyte size or adipogenesis could also explain the in vivo effects the authors observe.
16.
What is the evidence that Map kinase signaling leads to IRS1 serine phosphorylation?
17.
In the epididymal pad adenoviral injection studies, if the adenovirus was taken up into immune cells within the adipose tissue, would that give the expected effects that they observe?
18. Some references included in the text cannot be found in the bibliography (i.e. page 4, line 10, refers to Kaneto et al., 2004 , Luan et al., 2009 , manning & Davis 2003 ) -none of which are present in the bibliography.)
19. The fasting blood glucose values shown in figure 2E seem exceptionally high considering these mice were fasted for 16 hours.
20. Within the methods section please clarify the strains of mice/background used for the various components of the study and explain why they were selected.
21. This manuscript would also benefit from further proofreading. There are spelling mistakes, p4 line 15, i.e gen, should be gene. Supplemental Table 1 , the body weight column appears to be out of alignment with the other columns. In methods section, companies should be quoted with state, i.e. Cell signaling Technology, MA) Referee #3:
Review of EMBO article Yu et al Yu et al. have elegantly presented a tremendous amount of work. They show that Egr-1 is upregulated in diabetic humans and genetic or diet-induced obese mouse models, over-expression blunts insulin sensitivity in vivo and in vitro, dominant negative Egr-1 reverses insulin resistance in db/db mice and TNFa-induced insulin resistance. They show definitively that Egr-1 overexpression reciprocally regulates the PI3K/AKT (down) and ERK/MAPK (up) pathway through PTEN and GGPPS. Examination of cytokine expression in vivo and in vitro and co-culture studies nicely support mechanism of action. Overall, their work is very impressive in that they clearly investigate the role of Egr-1 in various models with complementary approaches. It is a novel and convincing manuscript. My concerns are overstatements and wrong word choice which can be corrected with very minor editing. Even the major comments are minor. I would change the title to be a bit more exciting and the current one does not represent the massive amount of work accomplished, especially since it says mice but they also have human data. "Adipose Egr-1 is upregulated in diabetic humans and animals and decreases insulin sensitivity by reciprocally regulating PI3K/AKT and MAPK pathways."
Major comments 1) Results Page 7 and used several times such as in figure legend for fig 1 on page 28: the authors say "constantly" elevated. However, they are only measuring 1 time point. Constantly implies elevations over several time points. Perhaps they mean consistently elevated between individuals? It may be easiest to just leave out a descriptor and say elevated. 2) Results Page 7 and throughout paper such as figure legend for fig 1 on page 28. Please write epi fat pad in text when referring to fat. Although it is in methods, I felt that it would be clearer if the authors stated in the results. Same for "adipocytes" later in manuscript. Please write 3T3L1 adipocytes so that the reader does not infer primary adipocytes. 3) Results Page 7-"Egr-1 exerts an effect" is not correct. You can't assume that it can exert an effect because you are not measuring that. Say "can be regulated" instead. 4) page 8 -sentence unclear. I do not understand what they mean at all. Ends with "epi fat pads that is visceral..." 5) page 8 -fig 2C conclusion overstated-it is not greatly impaired. Slightly is a more appropriate word. 6) page 12 -fig 5E conclusion. Say "slightly" or "minimally" more sensitive since there is only 1 time point different. Overall they are very very similar and you should be hesitant to say more sensitive. A clamp study would be able to definitively show increased insulin sensitivity in GGPPS-/-, but that is likely beyond the scope of this study. 7) page 15-I don't like the word "activating" as in "activating downstream genes involved in PI3K/AKT and MAPK signaling. Sustained "activating" Egr-1..." because activating implies activity such as a kinase activity or transcriptional activity. The authors should say "inducing the expression of downstream genes" or "sustained expression of Egr-1." 8) page 16-perhaps the authors can comments on the size of adipocytes where they mentioned data not shown. If the adipocytes are smaller, then they would be more insulin sensitive which would support their findings. 9) I hope that immunoblots shown are representative of larger human/animal studies. Please write in the figure legend that blots are representative. 10) figure legend 2C page 33-Egr-1 overexpression did not "greatly impair glucose tolerance". It slightly or minimally did. Please correct. 11) figure 1 image-page 34. In later figures authors denoted BKs or db/db under blots to help the reader. They should do the same for the first figure since there is so much data to get through. 12) sup fig S2 the authors show data for body weight and food intake when they injected Egr-1 and dnEgr-1. This should be mentioned in the text since it is relevant to systemic and hepatic insulin sensitivity. Also mention changes fat pad mass if obtained.
Minor comments:
It is impressive that they see effects in vivo after just 7 days of adenoviral injection into fat pads. I wonder if they would see stronger effects if they let the experiment go longer. (I am not asking for this since they have results, but perhaps results would be even stronger at 14 days for example). Very well written but needs some clarity with English. Some minor typos. Page 6, spell out BKs There could be exciting future studies in brown fat and/or macrophages, especially when using the FABP4 (aP2) driving CRE since aP2 is expressed in activated macrophages in adipose, atherosclerotic vessels, etc. Referee #1:
1. The authors showed that EGR1 expression was elevated in adipose tissue from diabetic patients and db/db mice compared with their controls. It is important to find out whether EGR1 expression was elevated in insulin resistant, a prediabetic state, or only in diabetic state. This is can be done by using ob or diet-induced obese C57bl6 mice.
Yes, it is very suggestive. So we detected the Egr-1 protein level in the HFD-induced B6 mice for different times (Figure 1G). We can find that the protein level of Egr-1 and GGPPS increased after 3 weeks of HFD induction and increased more after 6 weeks of HFD induction.
2. The information on patients' BMI has to be included in the supplemental Table 1 . In addition, information on which adipose depot where biopsies were taken from patients needs to be include. It has been shown that the gene expression in each fat depot and their contribution to insulin resistant is quite different. 2. In Figure 1 the loading levels are clearly unequal between normal and diabetics in Figure 1A . This clearly skews the results, and the data need to be accurately quantitated as a ratio of Egr1 or GGPPS to actin. The relationship between Figure 1 and Supplemental Figure 1 is not clear. Is the Supplemental figure the scanned results of the blots shown in Figure 1 ? How many replicates were performed in Figure 1A , C, E, and G, and please be explicit as to the quantitation of these Western blots by scanning and statistics. Figure 1A .
Yes, Supplemental Figure 1 is the densitometric results of the blots shown in Figure 1 . We have modified the description to make more clearly in the figure legend of Supplemental Figure 1 . There are 10 samples of diabetic patients and 10 of normal people that we collected in Figure 1A and five replicates mice in each group in Figure 1C 3. Supplemental Fig. 2 . It appears that there are small differences in body weight in the db/db mouse and over 7 days this could be significant. There also appears to be changes in food intake in the wild types with adenovirus injection. Could these changes affect the in vivo metabolic data?
The body weight data of mice we showed in Supplemental Fig. 2 Figure 2C) .
The result shows that most of the fat cells are infected. But we can not find lymphocyte invasion in injected fat tissue. We also detect the expression of some mark genes of immune cells (Supplemental Figure 6B) and find that macrophage infiltration mark gene Lysozyme, macrophages polarization mark genes, IL-4 and IL-13 have no change after virus injection, which suggests that the immune cells may not be affected by the virus infection.
5. Given the known effects of Egr-1, by what mechanism do the authors think IRS1 phosphorylation increases in Figure 2 , and how are the effects transmitted to the liver?
We have reported the mechanism by which IRS1 phosphorylation is affected by Egr-1 (Shen N, et, al., (2011) Journal of Biological Chemistry 286(16): 14508-14515). Egr-1 can promote ggpps transcription, which reactivate the Ras/MAPK/Erk1/2 pathway that can phosphorylate the IRS-1 on Serine 612 that is the inactivated site of IRS-1. The serine phosphorylation of IRS-1 impairs their interaction with the insulin receptor and consequently decreases their tyrosine phosphorylation by the insulin receptor (Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y (1997); A molecular basis for insulin resistance. Journal of Biological Chemistry 272(47): 29911). Thus, disruption of Egr-1 function could inhibit the IRS-1 phosphorylation on Serine 612 and make tyrosine phosphorylation increase.

Additionally, as we mentioned in the Discussion that adipose tissue is the body's largest endocrine organ. Egr-1 can affect the synthesis and release of cytokines, such as TNF-a and IL-6, which can regulate liver insulin sensitivity.
6. In the signaling studies, the authors are hypothesizing that Egr-1 "tilts the balance" of PI3 kinase/Akt signaling. However, while Akt is measured, no measures of PI3 kinase are included. It is mandatory that direct measures of PI3 kinase activity be provided throughout these experiments. Figure  3A , B, C, D.
We have measured the phosphorylation of PI3K under insulin treatment and embedded into
7. In Figure 4 , they provide nice evidence for the effect of Egr-1 mediated through PTEN and GGPPS. These studies again call for direct measurements of PI3 kinase. Given the targets of PTEN and GGPPS, how do the authors interpret the increased p-IRS-I data in Figure 2 ?
We have measured the phosphorylation of PI3K and embedded them in Figure 4D .
The increase of p-IRS-1-Tyr in fat by over dnEgr-1 expression in Figure 2 is due to Egr-1 dependent GGPPS transcription (See our report in Shen N, et, al., (2011) Journal of Biological Chemistry 286(16): 14508-14515). Increased GGPPS in db/db mice augments Ras prenylation and then reactivates Ras/MAPK/Erk1/2 pathway that can phosphorylate the IRS-1 on Serine 612. The serine phosphorylation of IRS-1 impairs their interaction with the insulin receptor and consequently decreases their tyrosine phosphorylation by the insulin receptor (Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y (1997); A molecular basis for insulin resistance. Journal of Biological Chemistry 272(47): 29911). Overexpression of dnEgr-1 in fat will decrease GGPPS expression and then inhibit Serine 612 phosphorylation, thus in turn causes the increase of p-IRS-1-Tyr.
8. In Figures 5A&B, they conduct long term experiments with insulin treatment. However, it has been well described that chronic hyperinsulinemia in vitro leads to dramatic down regulation of the insulin receptor and this would be through a mechanism that has nothing to do with the Egr-1 story.
In what way can they show that the effects they observed are due to the Egr-1 mechanism and not do to the well known insulin receptor down regulation? Furthermore, chronic hyperinsulinemia has been shown to increase IRS1 serine phosphorylation, which decreases downstream IRS1 signaling. Therefore, there are plenty of mechanisms already published, independent of Egr-1 which explains all of these results. In fact, wouldn't the dnEgr1 experiment indicate that the effects of insulin on receptor down regulation and IRS1 serine phosphorylation are blocked. This would be contrary to the authors' hypothesis, but measurements of insulin receptor surface content and IRS1 serine phosphorylation must be provided. Figure 5B) Shen N, et, al., (2011 
Yes, indeed, insulin receptor has been reported to decrease under hyperinsulinism and this has not been proved to do with the Egr-1. So we have detected the insulin receptor protein level and indeed the insulin receptor decreased along with the long term insulin treatment (Supplemental
) Journal of Biological Chemistry 286(16): 14508-14515), Egr-1 dependant the serine 612 phosphorylation of IRS-1 was increased under long term insulin treatment. So both insulin receptor decrease and Egr1dependant IRS-1 serine 612 phosphorylation contributes insulin resistance formation under hyperinsulinism stress. Disruption of Egr-1 could decrease serine 612 phosphorylation and increase the tyrosine phosphorylation of IRS-1 which enhances insulin signaling. Thus we think that the Egr-1-dependant IRS-1 activity also has effect on insulin signaling and the improved IRS-1 activity by disruption of Egr-1 may compensate the decrease of insulin receptor. We have discussed this in the text on Page 17 Line 330-335.
9. It is hard to see that the small differences in glucose levels in Figure 5E are meaningful. Given the large changes in 5D, it is hard to reconcile the small changes in 5E. 10. As a general comment, the measures of insulin sensitivity and glucose homeostasis are a bit superficial. This study would be greatly strengthened by more measurements of insulin secretion, circulating insulin levels, as well as glucose clamp studies in the various mouse models.
We agree with the reviewer's comment that more experiment should be done to study the function of Egr-1 on insulin resistance. We have followed the reviewer's suggestion by performing the glucose clamp studies to determine whether the whole-body insulin sensitivity has been improved after overexpression of dnEgr-1 in the epi fat tissue of db/db mice. The result has been shown in the Fig.5D .
11. Figure 5A is interesting, but these are cytokines not adipokines and the authors do not know the cellular origin of the cytokines. This begs the question as to what is the effect on circulating concentrations of adiponectin and leptin. This should be provided.
We have detected the adiponectin and leptin (Supplemental Figure 6) 12. In Figure 6D , the authors conclude that Egr-1 overexpression in fat blocked insulin induced Akt phosphorylation in the liver of BKs WT mice. However, there are two individual mice presented and pAkt looks very similar to GFP treatment in the first individual. Figure  6C) . Another reason is that there might be some differences in releasing and circulating cytokines after Egr-1 overexpression in fat and thus the response of liver is of course different.
13. The co-culture experiments in Figure 6F don't make much sense. They are showing that the coculture changes insulin stimulated glucose uptake in hepatocytes. However, insulin has no effect to stimulate glucose uptake in hepatocytes, unlike its well known effects in adipocytes and muscle cells. Therefore, how can they have insulin stimulated glucose uptake effects on this process with the various co-culture conditions measured, since it is not a part of insulin action in liver. Figure 6F. 14. In general, the manipulations of PTEN and GGPPS are interesting, but throughout the paper the authors tend to conflate these two discrete effects, since they are both end points of Egr-1s transcriptional effects. For example, the GGPPS adipocyte knockout mouse would be an interesting story all by itself, and the data presented in this manuscript on this interesting mouse model are very preliminary and superficial. 15. Egr-1 has been reported to have potent effects on adipocytes biology, independent of insulin signaling. In the discussion, the authors mention unpublished data on adipocyte size, etc. This should be presented in the manuscript, since changes in adipocyte size or adipogenesis could also explain the in vivo effects the authors observe.
Sorry that we make such a big mistake to detect glucose uptake in hepatocytes after insulin stimulation. We instead detect the glycogenesis in hepatocytes after co-cultured with adipocytes. Since insulin can increase glycogen synthase activity and glycogenesis in hepatocytes by triggering the PI3K/AKT and inactivating the GSK-3, then the free glucose in hepatocytes is decreased which indirectly causes glucose influx through Glut-2 in cell membrane. We added the glycogen synthesis result in the
We added this result in Supplemental Figure 2C . (Shen N, et, al., (2011) Journal of Biological Chemistry 286(16): 14508-14515) 17. In the epididymal pad adenoviral injection studies, if the adenovirus was taken up into immune cells within the adipose tissue, would that give the expected effects that they observe?
As we provided the evidence in the Supplemental Figure 6 , the virus injection did not affect the function of immune cells, such as infiltration and polarization. Thus, the immune cells in fat tissue would have no effect on insulin resistance.
18. Some references included in the text cannot be found in the bibliography (i.e. page 4, line 10, refers to Kaneto et al., 2004 , Luan et al., 2009 , manning & Davis 2003 -none of which are present in the bibliography.)
Sorry for the omission here and we have added these references into the text.
The mice we used in Figure 2E were the diabetic mice, thus the fasting basal blood glucose would be at a quite high level.
20. Within the methods section please clarify the strains of mice/background used for the various components of the study and explain why they were selected. 11) figure 1 image-page 34. In later figures authors denoted BKs or db/db under blots to help the reader. They should do the same for the first figure since there is so much data to get through.
We denoted the background of mice in the figure 1.
12) sup fig S2 the authors show data for body weight and food intake when they injected Egr-1 and dnEgr-1. This should be mentioned in the text since it is relevant to systemic and hepatic insulin sensitivity. Also mention changes fat pad mass if obtained.
We have described this in the text on Page 8 Line 146-148.
Minor comments: It is impressive that they see effects in vivo after just 7 days of adenoviral injection into fat pads. I wonder if they would see stronger effects if they let the experiment go longer. (I am not asking for this since they have results, but perhaps results would be even stronger at 14 days for example).
We Dear Dr. Li, Your revised manuscript has now been re-assessed by one of the original referees whose comments you will find enclosed. This scientist asks for two minor revisions. I kindly ask you to incorporate these and provide us with a final word-file of your paper to facilitate efficient acceptance.
Yours sincerely,
Editor
The EMBO Journal REFEREE REPORT:
The authors have revised the manuscript well. I have just two minor revisions. 1. Please include the body weight data of the db/db mice referred to in the original supplemental figure 2. 2. The authors show that the GGPPS ITT data (Fig 5E &F) is more striking when they include only make mice and not females. This suggests there is a gender specific effect and this should be referred to in the text.
